Identifying optimal serum 1,3-β-D-Glucan cut-off for diagnosing Pneumocystis Jirovecii Pneumonia in non-HIV patients in the intensive care unit

被引:0
作者
Li, Yuan-Yuan [1 ]
Chen, Yan [1 ]
Li, Shan [1 ]
Dong, Run [1 ]
Yang, Qi-Wen [2 ]
Peng, Jin-Min [1 ]
Du, Bin [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Med Intens Care Unit, 1 Shuaifuyuan, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Clin Lab, 1 Shuaifuyuan, Beijing 100730, Peoples R China
关键词
Pneumocystis Jirovecii pneumonia; (1,3)-beta-D-glucan; Intensive care unit; Diagnosis; Cut-off value; INVASIVE FUNGAL-INFECTIONS; CRITICALLY-ILL PATIENTS; BETA-D-GLUCAN; ASSAY; (1,3)-BETA-D-GLUCAN; PERFORMANCE;
D O I
10.1186/s12879-024-09873-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Serum (1,3)-beta-D-glucan (BDG) detection for diagnosis of Pneumocystis jirovecii pneumonia (PJP) in non-human immunodeficiency virus (HIV) immunocompromised patients lacks intensive care unit (ICU)-specific data. We aimed to assess its performance and determine the optimal cutoff for PJP in ICU population. Methods This retrospective study included critically ill non-HIV immunocompromised patients admitted to a medical ICU with suspected pneumonia, undergoing simultaneous microbiological testing for P. jirovecii on lower respiratory tract specimens and serum BDG. Confounders affecting BDG positivity were explored by multivariable logistic regression. Optimal cut-offs were derived from Youden's index for the entire cohort and subgroups stratified by confounders. Diagnostic performance of serum BDG was estimated at different cutoffs. Results Of 400 patients included, 42% were diagnosed with PJP and 58.3% had positive serum BDG. Serum BDG's area under the receiver operating characteristic curve was 0.90 (0.87-0.93). At manufacturer's 150 pg/ml cut-off, serum BDG had high sensitivity and negative predictive value (94%), but low specificity and positive predictive value (67%). Confounders associated with a positive serum BDG in PJP diagnosis included IVIG infusion within 3 days (odds ratio [OR] 9.24; 95% confidence interval [CI] 4.09-20.88, p < 0.001), other invasive fungal infections (OR 4.46; 95% CI 2.10-9.49, p < 0.001) and gram-negative bacteremia (OR 29.02; 95% CI 9.03-93.23, p < 0.001). The application of optimal BDG cut-off values determined by Youden's index (252 pg/ml, 390 pg/ml, and 202 pg/ml) specific for all patients and subgroups with or without confounders improved the specificity (79%, 74%, and 88%) and corresponding PPV (75%, 65%, and 85%), while maintaining reasonable sensitivity and NPV. Conclusions Tailoring serum BDG cutoff specific to PJP and incorporating consideration of confounders could enhance serum BDG's diagnostic performance in the ICU settings.
引用
收藏
页数:9
相关论文
共 33 条
  • [1] Albert O, Eur J Clin Microbiol Infect Dis, V30, P1450
  • [2] (1,3)-β-D-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies
    Azoulay, Elie
    Guigue, Nicolas
    Darmon, Michael
    Mokart, Djamel
    Lemiale, Virginie
    Kouatchet, Achille
    Mayaux, Julien
    Vincent, Francois
    Nyunga, Martine
    Bruneel, Fabrice
    Rabbat, Antoine
    Bretagne, Stephane
    Lebert, Christine
    Meert, Anne-Pascale
    Benoit, Dominique
    Pene, Frederic
    [J]. ONCOTARGET, 2016, 7 (16) : 21484 - 21495
  • [3] EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group
    Bassetti, Matteo
    Azoulay, Elie
    Kullberg, Bart-Jan
    Ruhnke, Markus
    Shoham, Shmuel
    Vazquez, Jose
    Giacobbe, Daniele Roberto
    Calandra, Thierry
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 72 : S121 - S127
  • [4] Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients
    Bienvenu, Anne-Lise
    Traore, Karim
    Plekhanova, Irina
    Bouchrik, Mourad
    Bossard, Cecile
    Picot, Stephane
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 46 : 11 - 17
  • [5] A Negative (1,3)-β-D-Glucan Result Alone Is Not Sufficient to Rule Out a Diagnosis of Pneumocystis Pneumonia in Patients With Hematological Malignancies
    Damiani, Celine
    Demey, Baptiste
    Pauc, Cecile
    Le Govic, Yohann
    Totet, Anne
    [J]. FRONTIERS IN MICROBIOLOGY, 2021, 12
  • [6] Diagnostic accuracy of serum (1-3)-β-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis
    Del Corpo, Olivier
    Butler-Laporte, Guillaume
    Sheppard, Donald C.
    Cheng, Matthew P.
    McDonald, Emily G.
    Lee, Todd C.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (09) : 1137 - 1143
  • [7] Serum (1-3)-β-D-Glucan as a Tool for Diagnosis of Pneumocystis jirovecii Pneumonia in Patients with Human Immunodeficiency Virus Infection or Hematological Malignancy
    Desmet, Stefanie
    Van Wijngaerden, Eric
    Maertens, Johan
    Verhaegen, Jan
    Verbeken, Eric
    De Munter, Paul
    Meersseman, Wouter
    Van Meensel, Britt
    Van Eldere, Johan
    Lagrou, Katrien
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2009, 47 (12) : 3871 - 3874
  • [8] Combination of β-(1,3)-D-glucan testing in serum and qPCR in nasopharyngeal aspirate for facilitated diagnosis of Pneumocystis jirovecii pneumonia
    Desoubeaux, Guillaume
    Chesnay, Adelaide
    Mercier, Victor
    Bras-Cachinho, Jose
    Moshiri, Parastou
    Eymieux, Sebastien
    De Kyvon, Marie-Alix
    Lemaignen, Adrien
    Goudeau, Alain
    Bailly, Eric
    [J]. MYCOSES, 2019, 62 (11) : 1015 - 1022
  • [9] Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients
    Digby, J
    Kalbfleisch, J
    Glenn, A
    Larsen, A
    Browder, W
    Williams, D
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (05) : 882 - 885
  • [10] Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
    Donnelly, J. Peter
    Chen, Sharon C.
    Kauffman, Carol A.
    Steinbach, William J.
    Baddley, John W.
    Verweij, Paul E.
    Clancy, Cornelius J.
    Wingard, John R.
    Lockhart, Shawn R.
    Groll, Andreas H.
    Sorrell, Tania C.
    Bassetti, Matteo
    Akan, Hamdi
    Alexander, Barbara D.
    Andes, David
    Azoulay, Elie
    Bialek, Ralf
    Bradsher, Robert W., Jr.
    Bretagne, Stephane
    Calandra, Thierry
    Caliendo, Angela M.
    Castagnola, Elio
    Cruciani, Mario
    Cuenca-Estrella, Manuel
    Decker, Catherine F.
    Desai, Sujal R.
    Fisher, Brian
    Harrison, Thomas
    Heussel, Claus Peter
    Jensen, Henrik E.
    Kibbler, Christopher C.
    Kontoyiannis, Dimitrios P.
    Kullberg, Bart-Jan
    Lagrou, Katrien
    Lamoth, Frederic
    Lehrnbecher, Thomas
    Loeffler, Jurgen
    Lortholary, Olivier
    Maertens, Johan
    Marchetti, Oscar
    Marr, Kieren A.
    Masur, Henry
    Meis, Jacques F.
    Morrisey, C. Orla
    Nucci, Marcio
    Ostrosky-Zeichner, Luis
    Pagano, Livio
    Patterson, Thomas F.
    Perfect, John R.
    Racil, Zdenek
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 71 (06) : 1367 - 1376